Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ju Fu Tang Biotech Holdings Co's EBIT per Share for the
six
months ended in Mar. 2026 was HK$0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was HK$0.08.
During the past 3 years, the average EBIT per Share Growth Rate was 2.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 13.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Ju Fu Tang Biotech Holdings Co's EBIT per Share or its related term are showing as below:
HKSE:08217'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -13.6 Med: 24.4 Max: 60.4
Current: 2.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Ju Fu Tang Biotech Holdings Co was 60.40% per year. The lowest was -13.60% per year. And the median was 24.40% per year.
HKSE:08217's 3-Year EBIT Growth Rate is ranked worse than 60.62% of 1394
companies
in the Construction industry
Industry Median: 9.2
vs HKSE:08217: 2.50
Ju Fu Tang Biotech Holdings Co (HKSE:08217) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Ju Fu Tang Biotech Holdings Co EBIT per Share Related Terms
Ju Fu Tang Biotech Holdings Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ju Fu Tang Biotech Holdings Co EBIT per Share Chart
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ju Fu Tang Biotech Holdings Co (HKSE:08217) has a EBIT per Share of HK$0.08 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Ju Fu Tang Biotech Holdings Co and its competitors. According to the industry distribution chart, Ju Fu Tang Biotech Holdings Co ranks #845 out of 1394 companies in the Construction industry, placing it in the top 60.6%.
Is Ju Fu Tang Biotech Holdings Co's EBIT per Share too high?
Ju Fu Tang Biotech Holdings Co's current EBIT per Share is HK$0.08. Based on the distribution chart, Ju Fu Tang Biotech Holdings Co ranks #845 out of 1394 companies in the Construction industry, which is below the industry midpoint. Overall, Ju Fu Tang Biotech Holdings Co has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ju Fu Tang Biotech Holdings Co's EBIT per Share compare to PWR and FIX?
According to the Construction industry distribution chart, Ju Fu Tang Biotech Holdings Co ranks #845 out of 1394 companies for EBIT per Share. This places Ju Fu Tang Biotech Holdings Co in the lower half of its industry. The industry median EBIT per Share is 9.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Construction company?
The median EBIT per Share among Construction companies is 9.20, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Ju Fu Tang Biotech Holdings Co and its competitors. For the Construction industry, the median EBIT per Share is 9.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ju Fu Tang Biotech Holdings Co's current EBIT per Share is HK$0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ju Fu Tang Biotech Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Ju Fu Tang Biotech Holdings Co (HKSE:08217) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.15, compared to a current price of HK$0.10 — trading 32% below its estimated fair value. The current EBIT per Share is HK$0.08. Ju Fu Tang Biotech Holdings Co's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Ju Fu Tang Biotech Holdings Co (HKSE:08217), the current EBIT per Share is HK$0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ju Fu Tang Biotech Holdings Co (HKSE:08217) Overvalued in 2026?
Based on GuruFocus' analysis, Ju Fu Tang Biotech Holdings Co stock appears to be undervalued.
The current stock price of HK$0.10 is trading 32% below its estimated GF Value™ of HK$0.15.
GuruFocus considers Ju Fu Tang Biotech Holdings Co to be Possible Value Trap.
Key valuation signals for HKSE:08217:
EBIT per Share: HK$0.08
GF Value™: HK$0.15 vs. price of HK$0.10 (32% below fair value)
No single metric tells the full story. See the HKSE:08217 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ju Fu Tang Biotech Holdings Co Ltd, formerly known as WMHW Holdings Ltd, is an investment holding company operating through its subsidiaries. It engaged in the provision of construction works and investment holding.
36GF Score
Get the complete analysis for HKSE:08217
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08217 has been successfully added to your 
